GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed price. Currency in GBp
1,523.00
-0.50 (-0.03%)
As of 8:46AM BST. Market open.
Stock chart is not supported by your current browser
Previous close1,523.50
Open1,526.00
Bid1,523.00 x 175400
Ask1,523.50 x 417900
Day's range1,521.00 - 1,527.50
52-week range1,444.00 - 1,724.50
Volume270,224
Avg. volume8,011,472
Market cap73.95B
Beta1.15
PE ratio (TTM)38.95
EPS (TTM)39.1
Earnings date25 Oct 2017
Forward Dividend & Yield1.01 (5.14%)
Ex-dividend date2017-08-10
1y target est1,715.69
  • Reuters9 hours ago

    Britain backs GSK's gene therapy for 'bubble boy' syndrome

    Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment. Britain's National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem cell transplant therapy.

  • Reuters - UK Focus9 hours ago

    Britain backs GSK's gene therapy for "bubble boy" syndrome

    GlaxoSmithKline's gene therapy for the so-called "bubble boy" disease was approved by Britain's healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros . Gene therapy is designed ...

  • FDA approves better vaccine against painful shingles virus
    Associated Press2 days ago

    FDA approves better vaccine against painful shingles virus

    U.S. regulators have approved a new, more effective vaccine to prevent painful shingles, which is caused by the chickenpox virus.

  • Reuters2 days ago

    GlaxoSmithKline adult shingles vaccine wins U.S. approval

    Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co (MRK.N). The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data. Glaxo said the U.S. Centers for Disease Control and Prevention's advisory committee on immunization practices is expected to vote on a recommendation for the use of Shingrix at its meeting on Wednesday.

  • Reuters - UK Focus2 days ago

    GlaxoSmithKline adult shingles vaccine wins U.S. approval

    Oct (Shenzhen: 000069.SZ - news) 20 (Reuters) - The U.S. Food and Drug Administration approved GlaxoSmithKline (Other OTC: GLAXF - news) 's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday. Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck (Jakarta: 28586808.JK - news) & Co. The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters (Dusseldorf: TOC.DU - news) data.

  • Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?
    Zacks3 days ago

    Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

    The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .

  • 3 High-Yield Pharmaceutical Stocks
    Motley Fool3 days ago

    3 High-Yield Pharmaceutical Stocks

    High-yield pharma stocks are rare, but these three offer comparatively fat payouts.

  • China Biotech Promise Struggles to Keep Foreign Innovators
    Bloomberg3 days ago

    China Biotech Promise Struggles to Keep Foreign Innovators

    As money rushes into China’s fledgling biotechnology sector, Eli Lilly & Co. and other foreign drugmakers are scaling back.

  • Reuters4 days ago

    China biotech's 'coming out party' masks long road ahead

    LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares in firms such as Chi-Med (HCM.L), Beigene (BGNE.O) and Zai Lab (ZLAB.O) have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (AZN.L).

  • Reuters - UK Focus4 days ago

    China biotech's 'coming out party' masks long road ahead

    LONDON/SHANGHAI, Oct (Shenzhen: 000069.SZ - news) 19 (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares (Berlin: DI6.BE - news) in firms such as Chi-Med, Beigene and Zai Lab have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (NYSE: AZN - news) .

  • What to Expect from Big Pharmas After J&J's Solid Q3 Results?
    Zacks4 days ago

    What to Expect from Big Pharmas After J&J's Solid Q3 Results?

    Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

  • Market Realist5 days ago

    What GlaxoSmithKline’s 3Q17 Performance Tells Us

    GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.

  • Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
    Zacks6 days ago

    Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

    GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

  • Reuters10 days ago

    GlaxoSmithKline's shingles vaccine gets approval in Canada

    (Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ...

  • Reuters - UK Focus11 days ago

    Sanofi boosts vaccines business with 170 mln euro investment

    VAL-DE-REUIL, France, Oct (Shenzhen: 000069.SZ - news) 12 (Reuters) - Sanofi (LSE: 0O59.L - news) on Thursday expressed confidence in the growth of its influenza vaccines after committing to invest 170 million euros to expand its manufacturing facility at Val-de-Reuil in north-western France. The new facility will allow Sanofi Pasteur, the group's vaccines arm, to expand the supply of VaxigripTetra, its newest "quadrivalent" vaccine, to up to 70 countries from around 20 currently. VaxigripTetra protects against four strains of the flu virus and competes with other quadrivalent and "trivalent" products already on the market.

  • Reuters - UK Focus11 days ago

    Sanofi invests 170 million euros in French vaccines facility

    Sanofi will invest 170 million euros to expand its vaccines manufacturing site at Val-de-Reuil in north-western France, in a drive aimed at boosting the production of one of its influenza vaccines. The ...

  • The Wall Street Journal11 days ago

    [$$] Ebola Vaccines Show Promise in New Study

    The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...

  • Pfizer weighs $15 bln sale of consumer healthcare business
    Reuters13 days ago

    Pfizer weighs $15 bln sale of consumer healthcare business

    The move comes as Germany's Merck KGaA (MRCG.DE) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years. Pfizer's consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.

  • Reuters - UK Focus13 days ago

    Two-year Brexit transition is assured, UK PM May tells business chiefs - source

    LONDON, Oct (Shenzhen: 000069.SZ - news) 9 (Reuters) - Prime Minister Theresa May told business leaders on Monday that they could be certain there would be a two-year transition period after Britain's exit from the European Union, a source told Reuters. May, who is trying to ease company concerns that Britain could crash out of the EU without a deal, met business chiefs from GlaxoSmithKline (Other OTC: GLAXF - news) , Vodafone and HSBC and other major companies to hear what they want from talks on Britain's post-Brexit relationship with the EU. Businesses have become alarmed by the slow progress of negotiations and the prospect that Britain could leave the trading bloc without a new trading arrangement in place in 2019.

  • May to consult business leaders on Brexit
    Reuters14 days ago

    May to consult business leaders on Brexit

    Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.

  • Reuters - UK Focus14 days ago

    Britain's May to consult business leaders on Brexit

    LONDON, Oct (Shenzhen: 000069.SZ - news) 9 (Reuters) - Britain's Prime Minister Theresa May will meet GlaxoSmithKline (Other OTC: GLAXF - news) , Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.

  • Fool.co.uk16 days ago

    GlaxoSmithKline plc is one of 10 top stocks for a Footsie starter portfolio

    G A Chester's quarterly review of 10 FTSE 100 (INDEXFTSE:UKX) industry giants, including GlaxoSmithKline plc (LON:GSK).

  • Reuters17 days ago

    FTSE at two-month peak as sterling falters

    British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning groups such as pharma stocks. The FTSE 100 index (.FTSE) closed 0.2 percent up at 7,522.87 points, with Britain's pound on track for its worst week in a year as the Prime Minister hit back at a plot to topple her, saying she would provide "calm leadership" to the country. "The talk of a leadership plot against the Prime Minister is eroding the pound's value and propping up the FTSE 100," CMC Markets analyst David Madden wrote in a note to clients.

  • Market Realist18 days ago

    Changes in GlaxoSmithKline’s Valuation

    As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.

  • Drug industry gives up legal battle over new UK cost curbs
    Reuters18 days ago

    Drug industry gives up legal battle over new UK cost curbs

    Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes